Objective The objective of this study was to analyse interand intra-country quantitative and qualitative differences in anti-asthmatic prescriptions to children and adolescents. Methods A literature search was performed in EMBASE and MEDLINE to identify pharmaco-epidemiological studies published from January 1, 2000 to December 31, 2008 in which anti-asthmatic prescription prevalence in out-hospital children was measured. A meta-analytic weighted average and 95% confidence intervals of prescription prevalences were calculated using a random-effect(s) model. Inter-and intra-country quantitative and, where possible, qualitative prescribing patterns were compared and assessed. Results Twelve studies were identified (ten from Europe, one from Canada and one from the USA), but epidemiological indicators varied widely, and only eight were suitable for meta-analysis. The data from these studies revealed intercountry quantitative differences in prescription prevalences in the overall population ≤19 years, with Italy having a prescription prevalence of 19.0%, Canada, 18.0%, USA, 14.6%, Denmark, 13.9%, Norway, 9.1% and the Netherlands, 6.2%. The overall prevalence was 13.3%. The analysis of qualitative inter-country differences revealed that, except for Italy, inhalatory short-acting β-agonists were the most prescribed, followed by inhalatory corticosteroids. Conclusions This first overall analysis of anti-asthmatic utilization studies in out-of-hospital children indicates a wide variability in anti-asthmatic prescription prevalence. It also reveals that epidemiological evaluations should be improved by using homogeneous indicators and, in order to validate the use of anti-asthmatic prescription as a proxy of disease, the diagnosis of asthma should accompany the data of prescriptions within the same population.
Introduction
Asthma is the most common chronic childhood illness, with a worldwide prevalence ranging between 1.5 and 32.6% in 2002 [1] . According to the global burden of disease from the 2004 World Health Organization (WHO) Health Report, in the population under age 14 years, asthma accounted for 9.5 (USA) and 8% (Europe) of total disability-adjusted lifeyears (DALY) lost per 1000 population [2] . Since asthma is a chronic disease, anti-asthmatic prescriptions should represent a proxy for asthma prevalence and, consequently, a tool for analyses of therapeutic appropriateness. This, however, is not true as it is for other chronic diseases because a gap exists between prescription rates and prevalence of disease due to both over-use and under-use of anti-asthmatics, in particular inhalatory corticosteroids (ICS). International guidelines recommend ICS for longterm control of persistent asthma for all degrees of severity, and inhalatory short-acting β-agonists (SABA), such as salbutamol, as first-choice therapy in an acute attack [3] [4] [5] . Although adherence to guidelines reduces the number of outpatient and emergency department visits [6] , guidelines are far from routinely applied in clinical practice [7] [8] [9] [10] . In paediatric practice, the main inadequacy seems to be the use of ICS: over-prescribed in upper respiratory tract infections (URTI) and not prescribed enough for prevention or maintenance therapy between acute attacks in asthmatic children and adults [11, 12] . On the other hand, the prescription of SABA for an URTI episode in the youngest group of patients, in which asthma is difficult to diagnose, would differentiate cases in which an asthma attack is triggered by a viral infection from non-asthmatic cases because only in the first case would therapy be efficacious.
With the aim of assessing the extent of anti-asthmatic prescriptions in children, we reviewed drug utilization studies, evaluating anti-asthmatic drug paediatric consumption data in the community setting from studies published between January 1, 2000 and December 31, 2008 and comparing inter-and intra-country anti-asthmatic prescribing patterns. The quantitative and qualitative analysis of prescribing patterns and the degree of adherence to guidelines would serve to identify areas in need of educational interventions to improve the appropriateness of asthma therapies for children.
Methods

Search strategy to identify studies
A literature search was conducted in June 2009 in the MEDLINE and EMBASE databases for all studies with original data on the pharmaco-epidemiological evaluation of anti-asthmatic drug prescriptions in outside-hospital communities that had been published between January 1, 2000 and December 31, 2008 (Fig. 1) . In order to analyse a comparable observation period, we excluded studies collecting data during or before 1998.
The MeSH search terms and additional keywords used in the search strategy were: drug utilization/drug prescriptions/ pharmaco-epidemiology; child/infant/adolescent; antiasthmatic agents/asthma. Manual searches for the bibliographies of retrieved articles were used to identify additional pertinent studies. Books and proceedings from meetings and congresses were not considered. The references retrieved were collected using the software program Reference Manager, ver. 11 (Institute for Scientific Information, Berkeley, CA). Only studies evaluating anti-asthmatic drug prescriptions in children in the general population outside the hospital setting were included. Studies focusing on asthmatic child populations only or on one anti-asthmatic class or drug only were excluded. Prevalence (number of children and adolescents who received at least one anti-asthmatic drug prescription per 100 individuals in the population) was used as the indicator. Prevalences were obtained from studies evaluating exclusively anti-asthmatic prescriptions and from studies evaluating all drug classes, including anti-asthmatics.
A qualitative, inter-country prescription analysis was performed by comparing, where possible, the percentages of utilization of the main classes of anti-asthmatics, including ICS, SABA, long-acting β-agonist (LABA) and leukotriene receptor antagonist (LTRA).
Anti-asthmatic prescription prevalence and asthma prevalence Prevalences of anti-asthmatic prescriptions obtained from identified studies were compared to asthma prevalences determined worldwide by The International Study of Asthma and Allergy in Childhood (ISAAC) [1] . Since ISAAC data were not available for Denmark, the Netherlands or Norway, a search of studies estimating asthma prevalence in these countries was performed [13] [14] [15] using MEDLINE and EMBASE.
Meta-analysis
The meta-analysis took into account only studies comparable for two indicators: source of data and age range. Thus, inclusion criteria for the meta-analysis were age range covering both preschoolers and adolescents (from 0 to 14-19 years) and regional, multi-regional, national or pharmacy dispensing and insurance plan database as the source of prescription data. Exclusion criteria were the lower age range groups and family paediatrician or general practitioner as the prescription source.
The meta-analytic weighted average and 95% confidence intervals (CI) of prescription prevalences were calculated using a random-effect(s) model to take into account the heterogeneity of the various studies [16, 17] .
Results
A total of 189 articles were retrieved from the literature databases, 86 from EMBASE, 83 from Medline and 20 from both. Of these, 176 were excluded, mainly because they focused on one class or drug only (30%), evaluated the impact of an educational intervention (30%) or analysed risk factors for asthma, ranging from socioeconomic indicators to therapy exposure, immunization, among others (30%). Three further studies were excluded because they analysed data collected before 1998 [18] [19] [20] . Only ten articles met the inclusion criteria (6%). After identifying two additional studies through a manual reference search (they were not retrieved using the database search because they not indexed with "anti-asthmatic agents" or "asthma" as a keyword), we had 12 pharmaco-epidemiological studies [9, 10, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] which met the inclusion criteria ( Fig. 1) . The studies were carried out from 1998 to 2006 in six countries: Italy and the Netherlands (three studies each), Denmark and Norway (two studies each), Canada and USA (one each) ( Table 1 ). There were substantial differences between the studies with regard to sample size (from a minimum of 6,417 to a maximum of 4,259,103 subjects), source of prescription data, and age classes considered. The data sources were mainly regional/multi-regional/national prescription databases taking part in periodical health care monitoring systems (six articles), followed by health insurance databases or pharmacy dispensing databases (two articles each) and family paediatricians or general practitioners (two articles). In terms of age, ten studies involved both preschool and school-aged children; one study was on 15-year-olds only and one study only looked at children in the 6-to 14-year-old age range. Seven of the surveys evaluated only anti-asthmatics, and five covered all drug categories. Prescribed anti-asthmatic prevalence ranged from 5 to 26% without any relationship with the observational period or with drug class analysed. Quantitative differences in anti-asthmatic use emerged among the six countries considered (Table 1 ). In general, two prescribing patterns could be identified, with some countries having high anti-asthmatic prescribing levels (Italy, USA and Canada) and others having low prescribing levels (Norway and the Netherlands). Eight out of twelve studies indicated that boys received more anti-asthmatic drug prescriptions than girls, and two articles [10, 26] reported that, after age 15, an opposite pattern appeared, with girls receiving more prescriptions than boys. The prescription prevalence by age reported by the majority of the studies decreased from 1-year-old infants to adolescence. One article reported an increasing trend from children in the age range 0-2 years to those aged 6 years and then a decrease from 6 years of age to adolescence [28] , and two studies reported the highest prevalence of prescriptions between ages 1 and 4 years [21, 23] .
Inter-country differences in anti-asthmatic treatment choices
Data on the distribution of prescriptions by anti-asthmatic classes were reported for all countries in the meta-analysis. In Italy, the ICS were the most prescribed class of drugs and covered 60% of anti-asthmatic prescriptions and 86% of the subjects treated, while SABA were the most prescribed class of drugs in the other countries, covering from 58 (USA) to 93% (Denmark) of anti-asthmatic users.
The percentage of ICS users varied from 25 (USA) to 67% (the Netherlands). Differences were found in the ICS/ SABA ratio, ranging from 0.35 in Denmark [25] to 0.84 in The Netherlands [30] . Three countries reported the most frequently prescribed anti-asthmatic drugs as follows: beclomethasone and salbutamol in Italy [21, 22] ; salbutamol and fluticasone in Canada [26] ; salbutamol and montelukast in the USA [27] . In Italy, beclomethasone and salbutamol are both prescribed mainly as nebulized suspension [21] . Table 2 compares Italy, USA and Canada, showing both the seven most frequently prescribed anti-asthmatics and that countries can [26] , 44% for Italy [20] , 39% for the Netherlands [28] and 26% for Denmark [25] . Only two countries reported distribution, analyzing the number of packages of anti-asthmatic drugs prescribed during the period studied: only 29% of Italian [21] and 26% of Dutch [30] subjects received three or more packages. Four articles [21, 26, 27, 30] reported similar percentages for oral steroids, from 4.0 to 4.7%. In only two articles was the prevalence of anti-asthmatic prescription checked against the diagnosis of asthma [28, 30] , and in both it was double.
Intra-country differences in prescription prevalence
The prevalence of anti-asthmatic prescriptions varied dramatically in Italy, ranging from 12 to 26% [21, 23] . It also varied in Denmark, ranging from 7.7 to 13.9% [25, 28] .
Meta-analysis
The meta-analysis was performed on eight of the 12 articles (Fig. 2) . Four studies were excluded because the age group and source of data were not comparable with the majority of the studies. Basically, the two studies on 15-year-old adolescents only [24] only and children aged 6-14 years only [28] as well as the two articles whose sources were family paediatricians or general practitioners [22, 30] were excluded from the meta-analysis. The overall prevalence was 13.3% (95% CI 9.4-17.1%), with Italian children the most exposed to anti-asthma therapy (19.0%, CI 5.3-32.7%) and Dutch children the least (6.2%, CI 3.8-8.5%). However, the addition of the four excluded articles to the meta-analysis did not significantly change the overall prevalence.
Inter-country differences between prescription prevalence and asthma prevalence gap
Our comparison of prescription prevalence data with published data on asthma prevalence (Fig. 2) indicated that in Denmark, the Netherlands, Norway and Canada, asthma prevalence and prescription prevalence are comparable. In the USA, prescription prevalence appears to be less than asthma prevalence, whereas in Italy, prescription prevalence was approximately twofold higher than asthma prevalence.
Discussion
This is the first analysis that specifically compares published drug utilization studies on anti-asthmatic prescriptions in the outside-hospital setting in children. One major limitation to such comparative studies, as underlined in a recent review on drug utilization studies [31] , is the wide variety of studies, with differences in study type (design and method), populations (in terms of sample size and age groups), and data collected, making comparative evaluation difficult or at best incomplete. Another limitation that we encountered is that data were available for comparison between only six countries, most of which were European. This is a very important limitation since countries with the highest asthma prevalence (≥10%), as reported by the ISAAC studies [1, 32] , are the USA, Canada, Australia, New Zealand, South America, England and Scotland, and studies on anti-asthma drug utilization in children from these countries are limited or lacking. However, the main limitation is the lack of data on asthma diagnosis, which would validate the appropriateness of anti-asthmatic utilization. In order to overcome the lack of these data, we attempted to use published asthma prevalence data for comparison with drug prescriptions. However, the sources are different (ISAAC reported data from only three of the six countries analysed), which represents yet another limitation. (14) Flunisolide (17) Budesonide (10) Beclomethasone (14) Budesonide (15) Levalbuterol (10) Terbutaline (8) Fluticasone (12) Fluticasone + salmeterol (9) Montelukast (5) Salbutamol in combination(5) Fluticasone (7) Sodium cromoglycate (2) Montelukast (3) Pirbuterol (1) Values in parenthesis are given as the percentage of the total number of treated subjects
The sum exceeds 100 because some children were prescribed more than one drug.
a Observation period
Inter-country quantitative differences
Large differences in the anti-asthmatic prescription prevalence were found between countries. The highest was in Italy and Canada and the lowest was in the Netherlands. If the high ranking of Canada can be justified by a high prevalence of asthma, the same is not true for Italy, where the prescribing pattern for antibiotics shows a similar profile [31, 33] . This result suggests that the differences in drug prescription rates may be attributable to different prescribing attitudes and national drug regulatory policies more than differences in the prevalence of asthma. Moreover, it is likely that anti-asthmatics and antibiotics are both used in URTI, even if this is not the first-line approach suggested by guidelines [3] [4] [5] .
Inter-country qualitative differences
Together with anti-asthmatic prescription prevalences, some differences also emerged in the quality of the drugs prescribed, although not all studies reported information on anti-asthmatic distribution by class and/or drug. Asthma, by definition, involves acute attacks of wheezing, the guidelines for which recommend treatment with SABA and prevention with ICS, so the percentage of patients receiving only one class of antiasthma drugs should be minimal. The fact that the prevalence of prescriptions was validated by a diagnosis of asthma in only two studies [28, 30] and that only four studies reported the percentage of children receiving more than one anti-asthma drug class made it difficult to evaluate adherence to guidelines. However, the percentages of patients receiving polytherapy (more than one class of anti-asthmatics) were 52% for Canada [26] , 44% for Italy [21] , 39% for the Netherlands [28] and 26% for Denmark [25] , suggesting either a lack of illness or, possibly, under-use of ICS for prevention/ maintenance therapy, as underlined in the U.S.A study [27] . This wide range is also partly highlighted by the differences in the ICS/SABA ratios, which range from 0.35 in Denmark [25] to 0.84 in the Netherlands [30] . While in the USA the low ICS prescription prevalence (low ICS/ SABA) might be explained by the higher prescription rate for montelukast [27] , in other countries the low ICS/SABA 8.4 [1, 32] 7.3 [13] 11.7 [14] 8.6 [15] 18.0 [1, 32] 22.3 [1, 32] ratio might suggest that, in addition to the cases in which SABA are used as therapy in the youngest patients, who are not yet easy to diagnose, the prescribing attitude is not only quantitatively but also qualitatively different. Only in the U.S. study was montelukast prescribed more than ICS. A detailed comparison of the most prescribed anti-asthma drugs was possible only between the USA, Canada and Italy (see Table 2 ), and even then the observation periods were different. Montelukast entered the market in 1998, and since data for the Canadian study was collected shortly thereafter, the difference found may not reflect an actual difference, rather it may be due to the fact that for new drugs, prescribing patterns tend to take 1 year or so to penetrate the market, especially in an area such as asthma where many existing, effective agents have already been approved.
Intra-country differences in prescription prevalence
The prevalence of anti-asthmatic prescriptions varied dramatically in Italy, ranging from 12 to 26% [21, 23] and similarly but slightly less in Denmark where it ranged from 7.7 to 13.9% [25, 28] . The reason for this diversity in the two Italian articles might be the different geographic setting: a single local health unit versus the multi-regional setting. The different prevalences in the two Danish articles might be due to the age group difference: the lower prescription prevalence study involved 6-14 year olds, an age group in which asthma is theoretically better diagnosed and treated, while the higher prevalence study included preschoolers, an age at which there is still a high percentage of the occasional wheezer.
Incongruence between prescription prevalence and asthma prevalence It must be noted that a precise comparison between prescription prevalence and asthma prevalence is difficult due to the lack of a single source of data on worldwide asthma prevalence that have been gathered in a homogenous manner.
The comparison between prescription prevalence and asthma prevalence shown in Fig. 2 indicates that asthma prevalence and prescription prevalence are comparable in Denmark, the Netherlands, Norway and Canada. In the USA, prescription prevalence appears to be less than asthma prevalence, and in Italy, prescription prevalence is double that of asthma prevalence. This comparison is only indicative because the reported asthma prevalences were measured in the >6-year-old group of subjects, an age at which the need for asthma medication decreases. Moreover, asthma prevalences were estimated by ISAAC and by questionnaire in some studies [1, [13] [14] [15] , and data may overestimate the burden of disease. In the case of the USA, the subjects might be undertreated and in the case of Italy, they may be overtreated, as suggested by the authors of the respective studies [23, 27] . However, even in the countries in which asthma and prescription prevalence are similar, the possibility that anti-asthmatics are also prescribed for diseases other than asthma is still valid because two studies [21, 26] found that half the subjects received only one package of antiasthma drugs per year, which is suggestive of non-asthmatic illness. Although the two articles reporting on the diagnosis of asthma [28, 30] were from countries (Denmark and the Netherlands) in which the prevalence of asthma is low, the gap between prescription prevalence and burden of disease was large, with the number of treated being twofold higher than the number of diagnosed cases. Since asthma is more reliably diagnosed in children from the age of 6 years, the discrepancy between prescriptions and actual disease does not necessarily suggest inadequacies in prescription, but it does point to anti-asthma drug use as therapy in the youngest patients, when asthma is suspected but not yet diagnosed. This was not confirmed by the Dutch report [30] which validated prescription prevalence by asthma diagnosis: in two age ranges (<6 and ≥6 years) the gap between asthma prevalence (diagnosed) and prescription prevalence in the youngest did not differ from that in the older children.
This analysis suggests two inadequacies in asthma treatment: (1) the sub-optimal prescription of ICS to asthma patients for prevention or maintenance; (2) the prescription of asthma medications to non-asthmatic subjects. For confirmation of these results, data from more homogenous studies are needed. Knowledge of the anti-asthmatic prescribing patterns of primary care physicians in the paediatric population is extremely important, since children are a prime target for inadequate prescription behaviour. The guidelines alone are not enough to ensure the correct use of anti-asthmatics, since physician adherence and compliance to guidelines are not obvious or common. Another widely debated topic related to compliance with asthma treatments is the education of asthmatic children and their care-givers. A recent meta-analysis [34] of U.S. studies confirms a reduction in hospitalization when children are educated about their disease, including sports practice, under preventive therapy, even if a diagnosis of asthma has been made.
In conclusion, this is the first analysis that specifically compares drug utilization studies on anti-asthmatic prescriptions in children outside the hospital setting. Despite the availability of data on the patterns of medication use in only six countries and the heterogeneity of the included studies, concordance with a divergence from community-based prevalences of asthma and symptoms might indicate different health beliefs among doctors and patients. Multi-national collaborative pharmaco-epidemiological studies aimed at collecting valid and comparable data are required, especially in those areas indicated by ISAAC as having a very high prevalence of asthma. These studies would be validated by diagnosis and outcome measures (e.g. number of emergency visits to the physician's office or emergency centers, or hospitalizations) and quality of life measures (e.g. number of exacerbations and days of school missed per year, presence of daily or nightly cough or wheeze, presence of cough or wheeze with exercise).
